ISLAMABAD, Oct 11: A bill for creating a Drug Regulatory Authority of Pakistan (DRAP), drafted in the aftermath of the ephedrine scandal, suggests that a specific director oversee the business of controlled and psychotropic drugs.

“It (the bill) is with the parliament and a committee of the National Assembly has already approved it,” federal minister for regulations and services, Dr Firdous Ashiq Awan, told Dawn.

She hoped the bill would soon become law and lead to better standards and controls in the pharmaceutical industry and prove “a win-win situation for all - the industry, the government and the patients”.

She said the policy board of DRAP will frame the regulations for the drug industry. “No pharmaceutical company owner will be considered for the membership of the board,” she added.

When established, the new drug regulatory authority would replace an ordinance that President Asif Ali Zardari promulgated in February this year after more 100 patients died in Punjab of adverse reaction of a drug for heart ailments.

Though the existing Drug Regulatory Agency of Pakistan that the ordinance created had the same objectives, the political storm the ephedrine scandal kicked up forced tightening of the drug control law.

Unlike the Agency which has ‘members’ on its board, the Authority is proposed to have directors for pricing, licensing and quality control, registration of drugs, biological and medical devices, pharmacy services, legal affairs, Information Technology, administration, human resource and development, and, additionally, a director for controlled and psychotropic drugs.

“This (last) position is needed to avert scams, like the one haunting the government now, in future,” said an officer of the Ministry of Regulations and Services.

‘Independent’ drug inspectors are to be appointed to regulate the trade in ‘controlled drugs'.

“We have to come hard on regulation,” the officer said. “The International Narcotics Control Board had expressed concern over the free availability of controlled drugs in Pakistan.”

New regulatory measures would create more than 1,000 jobs in different fields in the pharmaceutical industry, said another officer.

Opinion

Editorial

Judiciary’s SOS
Updated 28 Mar, 2024

Judiciary’s SOS

The ball is now in CJP Isa’s court, and he will feel pressure to take action.
Data protection
28 Mar, 2024

Data protection

WHAT do we want? Data protection laws. When do we want them? Immediately. Without delay, if we are to prevent ...
Selling humans
28 Mar, 2024

Selling humans

HUMAN traders feed off economic distress; they peddle promises of a better life to the impoverished who, mired in...
New terror wave
Updated 27 Mar, 2024

New terror wave

The time has come for decisive government action against militancy.
Development costs
27 Mar, 2024

Development costs

A HEFTY escalation of 30pc in the cost of ongoing federal development schemes is one of the many decisions where the...
Aitchison controversy
Updated 27 Mar, 2024

Aitchison controversy

It is hoped that higher authorities realise that politics and nepotism have no place in schools.